# Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma

## Metadata
**Authors:** Lars P Jordheim, Vincent Ribrag, Hervé Ghesquieres, Sophie Pallardy, Richard Delarue, Hervé Tilly, Corinne Haioun, Fabrice Jardin, Delphine Demangel, Gilles A Salles, Charles Dumontet
**Journal:** Haematologica
**Date:** 2015 May
**DOI:** [10.3324/haematol.2014.120113](https://doi.org/10.3324/haematol.2014.120113)
**PMID:** 25637052
**PMCID:** PMC4420233
**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420233/
**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC4420233/pdf/100e204.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC4420233/pdf/100e204.pdf)

## Acknowledgments

The authors would like to thank Anne-Laure Borel and Aurelie Verney for technical assistance.

## Footnotes

## References

1. Gemmati D, Ongaro A, Tognazzo S, et al. Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin’s lymphoma patients: association with toxicity and survival. Haematologica. 2007;92(4):478–485.  [DOI](https://doi.org/10.3324/haematol.10587) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/17488658/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Haematologica&title=Methylenetetrahydrofolate%20reductase%20C677T%20and%20A1298C%20gene%20variants%20in%20adult%20non-Hodgkin%E2%80%99s%20lymphoma%20patients:%20association%20with%20toxicity%20and%20survival&author=D%20Gemmati&author=A%20Ongaro&author=S%20Tognazzo&volume=92&issue=4&publication_year=2007&pages=478-485&pmid=17488658&doi=10.3324/haematol.10587&)

2. Kim IS, Kim HG, Kim DC, et al. ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy. Cancer Sci. 2008;99(12):2496–2501.  [DOI](https://doi.org/10.1111/j.1349-7006.2008.00985.x) | [PMC free article](/articles/PMC11159449/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/19032367/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cancer%20Sci&title=ABCG2%20Q141K%20polymorphism%20is%20associated%20with%20chemotherapy-induced%20diarrhea%20in%20patients%20with%20diffuse%20large%20B-cell%20lymphoma%20who%20received%20frontline%20rituximab%20plus%20cyclophosphamide/doxorubicin/vincristine/prednisone%20chemotherapy&author=IS%20Kim&author=HG%20Kim&author=DC%20Kim&volume=99&issue=12&publication_year=2008&pages=2496-2501&pmid=19032367&doi=10.1111/j.1349-7006.2008.00985.x&)

3. Ribrag V, Koscielny S, Casasnovas O, et al. Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. Blood. 2009;113(14):3307–3313.  [DOI](https://doi.org/10.1182/blood-2008-03-148874) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/18768784/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Blood&title=Pharmacogenetic%20study%20in%20Hodgkin%20lymphomas%20reveals%20the%20impact%20of%20UGT1A1%20polymorphisms%20on%20patient%20prognosis&author=V%20Ribrag&author=S%20Koscielny&author=O%20Casasnovas&volume=113&issue=14&publication_year=2009&pages=3307-3313&pmid=18768784&doi=10.1182/blood-2008-03-148874&)

4. Jamieson D, Boddy AV. Pharmacogenetics of genes across the doxorubicin pathway. Expert Opin Drug Metab Toxicol. 2011; 7(10):1201–1210.  [DOI](https://doi.org/10.1517/17425255.2011.610180) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/21919804/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Expert%20Opin%20Drug%20Metab%20Toxicol&title=Pharmacogenetics%20of%20genes%20across%20the%20doxorubicin%20pathway&author=D%20Jamieson&author=AV%20Boddy&volume=7&issue=10&publication_year=2011&pages=1201-1210&pmid=21919804&doi=10.1517/17425255.2011.610180&)

5. Amin ML. P-glycoprotein Inhibition for Optimal Drug Delivery. Drug Target Insights. 2013;7:27–34.  [DOI](https://doi.org/10.4137/DTI.S12519) | [PMC free article](/articles/PMC3762612/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/24023511/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Drug%20Target%20Insights&title=P-glycoprotein%20Inhibition%20for%20Optimal%20Drug%20Delivery&author=ML%20Amin&volume=7&publication_year=2013&pages=27-34&pmid=24023511&doi=10.4137/DTI.S12519&)

6. Yao S, Sucheston LE, Zhao H, et al. Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J. 2014;14(3):241–247.  [DOI](https://doi.org/10.1038/tpj.2013.32) | [PMC free article](/articles/PMC3940691/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/23999597/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pharmacogenomics%20J&title=Germline%20genetic%20variants%20in%20ABCB1,%20ABCC1%20and%20ALDH1A1,%20and%20risk%20of%20hematological%20and%20gastrointestinal%20toxicities%20in%20a%20SWOG%20Phase%20III%20trial%20S0221%20for%20breast%20cancer&author=S%20Yao&author=LE%20Sucheston&author=H%20Zhao&volume=14&issue=3&publication_year=2014&pages=241-247&pmid=23999597&doi=10.1038/tpj.2013.32&)

7. Varatharajan S, Abraham A, Zhang W, et al. Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia. Eur J Clin Pharmacol. 2012;68(12):1577–1586.  [DOI](https://doi.org/10.1007/s00228-012-1291-9) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/22562609/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Clin%20Pharmacol&title=Carbonyl%20reductase%201%20expression%20influences%20daunorubicin%20metabolism%20in%20acute%20myeloid%20leukemia&author=S%20Varatharajan&author=A%20Abraham&author=W%20Zhang&volume=68&issue=12&publication_year=2012&pages=1577-1586&pmid=22562609&doi=10.1007/s00228-012-1291-9&)

8. Bains OS, Karkling MJ, Grigliatti TA, Reid RE, Riggs KW. Two non-synonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin. Drug Metab Dispos. 2009;37(5):1107–1114.  [DOI](https://doi.org/10.1124/dmd.108.024711) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/19204081/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Drug%20Metab%20Dispos&title=Two%20non-synonymous%20single%20nucleotide%20polymorphisms%20of%20human%20carbonyl%20reductase%201%20demonstrate%20reduced%20in%20vitro%20metabolism%20of%20daunorubicin%20and%20doxorubicin&author=OS%20Bains&author=MJ%20Karkling&author=TA%20Grigliatti&author=RE%20Reid&author=KW%20Riggs&volume=37&issue=5&publication_year=2009&pages=1107-1114&pmid=19204081&doi=10.1124/dmd.108.024711&)

9. Bains OS, Szeitz A, Lubieniecka JM, et al. A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin. J Pharmacol Exp Ther. 2013; 347(2):375–387.  [DOI](https://doi.org/10.1124/jpet.113.206805) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/23995598/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Pharmacol%20Exp%20Ther&title=A%20correlation%20between%20cytotoxicity%20and%20reductase-mediated%20metabolism%20in%20cell%20lines%20treated%20with%20doxorubicin%20and%20daunorubicin&author=OS%20Bains&author=A%20Szeitz&author=JM%20Lubieniecka&volume=347&issue=2&publication_year=2013&pages=375-387&pmid=23995598&doi=10.1124/jpet.113.206805&)

10. Lal S, Sandanaraj E, Wong ZW, et al. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci. 2008;99(10):2045–2054.  [DOI](https://doi.org/10.1111/j.1349-7006.2008.00903.x) | [PMC free article](/articles/PMC11160041/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/19016765/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cancer%20Sci&title=CBR1%20and%20CBR3%20pharmacogenetics%20and%20their%20influence%20on%20doxorubicin%20disposition%20in%20Asian%20breast%20cancer%20patients&author=S%20Lal&author=E%20Sandanaraj&author=ZW%20Wong&volume=99&issue=10&publication_year=2008&pages=2045-2054&pmid=19016765&doi=10.1111/j.1349-7006.2008.00903.x&)

11. Gonzalez-Covarrubias V, Kalabus JL, Blanco JG. Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER). Pharm Res. 2008;25(7):1730–1734.  [DOI](https://doi.org/10.1007/s11095-008-9592-5) | [PMC free article](/articles/PMC2897163/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/18449627/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pharm%20Res&title=Inhibition%20of%20polymorphic%20human%20carbonyl%20reductase%201%20(CBR1)%20by%20the%20cardioprotectant%20flavonoid%207-monohydroxyethyl%20rutoside%20(monoHER)&author=V%20Gonzalez-Covarrubias&author=JL%20Kalabus&author=JG%20Blanco&volume=25&issue=7&publication_year=2008&pages=1730-1734&pmid=18449627&doi=10.1007/s11095-008-9592-5&)

12. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J. 2007;7(3):154–179.  [DOI](https://doi.org/10.1038/sj.tpj.6500413) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/16969364/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pharmacogenomics%20J&title=ABCB1%20genotype%20and%20PGP%20expression,%20function%20and%20therapeutic%20drug%20response:%20a%20critical%20review%20and%20recommendations%20for%20future%20research&author=GD%20Leschziner&author=T%20Andrew&author=M%20Pirmohamed&author=MR%20Johnson&volume=7&issue=3&publication_year=2007&pages=154-179&pmid=16969364&doi=10.1038/sj.tpj.6500413&)

13. Milani L, Gupta M, Andersen M, et al. Allelic imbalance in gene expression as a guide to cis-acting regulatory single nucleotide polymorphisms in cancer cells. Nucleic Acids Res. 2007;35(5):e34.  [DOI](https://doi.org/10.1093/nar/gkl1152) | [PMC free article](/articles/PMC1865061/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/17267408/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nucleic%20Acids%20Res&title=Allelic%20imbalance%20in%20gene%20expression%20as%20a%20guide%20to%20cis-acting%20regulatory%20single%20nucleotide%20polymorphisms%20in%20cancer%20cells&author=L%20Milani&author=M%20Gupta&author=M%20Andersen&volume=35&issue=5&publication_year=2007&pages=e34&pmid=17267408&doi=10.1093/nar/gkl1152&)

14. Kalabus JL, Cheng Q, Blanco JG. MicroRNAs differentially regulate carbonyl reductase 1 (CBR1) gene expression dependent on the allele status of the common polymorphic variant rs9024. PLoS One. 2012;7(11):e48622.  [DOI](https://doi.org/10.1371/journal.pone.0048622) | [PMC free article](/articles/PMC3486798/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/23133646/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=PLoS%20One&title=MicroRNAs%20differentially%20regulate%20carbonyl%20reductase%201%20(CBR1)%20gene%20expression%20dependent%20on%20the%20allele%20status%20of%20the%20common%20polymorphic%20variant%20rs9024&author=JL%20Kalabus&author=Q%20Cheng&author=JG%20Blanco&volume=7&issue=11&publication_year=2012&pages=e48622&pmid=23133646&doi=10.1371/journal.pone.0048622&)

15. Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003; 102(13):4284–4289.  [DOI](https://doi.org/10.1182/blood-2003-02-0542) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/12920037/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Blood&title=Intensive%20conventional%20chemotherapy%20(ACVBP%20regimen)%20compared%20with%20standard%20CHOP%20for%20poor-prognosis%20aggressive%20non-Hodgkin%20lymphoma&author=H%20Tilly&author=E%20Lepage&author=B%20Coiffier&volume=102&issue=13&publication_year=2003&pages=4284-4289&pmid=12920037&doi=10.1182/blood-2003-02-0542&)
